About CLS
News and insights
©Copyright 2025 CLS AB. All rights reserved.
MM-2022-025/Rev2
Start Investor Relations
Clinical Laserthermia Systems (CLS) is listed on Nasdaq First North Growth Market. Our aim is to provide relevant and transparent information for analysts, investors and media with the latest financial reports, events, news and the development of CLS’s share.
06/27/2025 Annual General Meeting
08/22/2025 Interim Report 2/25 January – June
11/14/2025 Interim Report 3/25 January – September
02/20/2026 Year-end report 2025
Recorded 16 May 2025
CLS provides minimally invasive, cost-efficient solutions for soft tissue resection in patients with complex medical conditions. Using high-precision laser energy, guided by imaging and real-time control, our patented thermotherapy platform enables safe, effective thermal ablation.
Focused initially on neurosurgery, CLS is expanding into adjacent areas. CLS’s business focuses on in-house development and market approval of medical devices. Our regulatory-approved devices are then commercialized through strategic partners in the U.S. and Europe, with a vision to do so on a global scale.
Our business model generates >60% gross margin with revenue from system sales and recurring revenue from procedure-based disposables, and supports rapid scaling across multiple therapeutic areas with minimal fixed costs.
Your subscription is now saved and you will recive an email to verify your email address and activate the subscription.
We could not save your subscriptions please go back and try again.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
©Copyright 2025 CLS AB. All rights reserved.
MM-2022-025/Rev2